Jennifer Richer
Concepts (455)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 16 | 2025 | 205 | 6.360 |
Why?
| | Receptors, Androgen | 14 | 2025 | 155 | 5.700 |
Why?
| | Breast Neoplasms | 47 | 2026 | 2318 | 4.480 |
Why?
| | MicroRNAs | 17 | 2018 | 698 | 3.580 |
Why?
| | Androgen Receptor Antagonists | 8 | 2021 | 35 | 2.320 |
Why?
| | Anoikis | 7 | 2021 | 31 | 2.140 |
Why?
| | Receptors, Estrogen | 15 | 2025 | 425 | 2.080 |
Why?
| | Gene Expression Regulation, Neoplastic | 35 | 2025 | 1487 | 2.040 |
Why?
| | Cell Line, Tumor | 40 | 2026 | 3611 | 2.010 |
Why?
| | Phenylthiohydantoin | 7 | 2025 | 44 | 1.890 |
Why?
| | Tryptophan | 4 | 2024 | 181 | 1.860 |
Why?
| | Estrogen Receptor alpha | 6 | 2022 | 147 | 1.770 |
Why?
| | Receptors, Progesterone | 24 | 2016 | 344 | 1.760 |
Why?
| | Tryptophan Oxygenase | 5 | 2024 | 34 | 1.600 |
Why?
| | Ovarian Neoplasms | 6 | 2024 | 586 | 1.100 |
Why?
| | Palmitates | 1 | 2025 | 21 | 0.950 |
Why?
| | Neoplasm Invasiveness | 4 | 2024 | 518 | 0.950 |
Why?
| | Progesterone | 16 | 2014 | 258 | 0.950 |
Why?
| | Benzamides | 8 | 2026 | 223 | 0.940 |
Why?
| | Tamoxifen | 10 | 2016 | 204 | 0.900 |
Why?
| | Progestins | 6 | 2014 | 85 | 0.900 |
Why?
| | Drug Resistance, Neoplasm | 8 | 2025 | 875 | 0.890 |
Why?
| | Alveolar Epithelial Cells | 1 | 2026 | 121 | 0.880 |
Why?
| | Oxidative Phosphorylation | 1 | 2025 | 209 | 0.870 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2024 | 58 | 0.860 |
Why?
| | Ribonuclease III | 2 | 2016 | 44 | 0.810 |
Why?
| | Neoplastic Stem Cells | 3 | 2017 | 414 | 0.790 |
Why?
| | DEAD-box RNA Helicases | 2 | 2016 | 90 | 0.780 |
Why?
| | Epithelial Cells | 3 | 2022 | 1125 | 0.780 |
Why?
| | Wound Healing | 1 | 2026 | 357 | 0.780 |
Why?
| | Epithelial-Mesenchymal Transition | 5 | 2018 | 219 | 0.770 |
Why?
| | Adipokines | 2 | 2024 | 53 | 0.750 |
Why?
| | Biomarkers, Tumor | 7 | 2021 | 1282 | 0.740 |
Why?
| | Cell Proliferation | 14 | 2021 | 2542 | 0.730 |
Why?
| | Kallikreins | 1 | 2021 | 26 | 0.720 |
Why?
| | Nitriles | 7 | 2025 | 193 | 0.710 |
Why?
| | Gene Expression Profiling | 11 | 2018 | 1794 | 0.680 |
Why?
| | Prostate-Specific Antigen | 1 | 2021 | 166 | 0.670 |
Why?
| | Female | 66 | 2026 | 77251 | 0.650 |
Why?
| | Membrane Transport Proteins | 1 | 2021 | 156 | 0.650 |
Why?
| | Endometrial Neoplasms | 6 | 2011 | 196 | 0.650 |
Why?
| | RNA, Long Noncoding | 2 | 2022 | 176 | 0.650 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2023 | 1095 | 0.650 |
Why?
| | Immunohistochemistry | 8 | 2017 | 1736 | 0.640 |
Why?
| | Trophoblasts | 1 | 2022 | 212 | 0.630 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2021 | 169 | 0.620 |
Why?
| | Pulmonary Alveoli | 1 | 2022 | 392 | 0.620 |
Why?
| | Transcription Factors | 13 | 2023 | 1754 | 0.620 |
Why?
| | Androgen Antagonists | 3 | 2017 | 92 | 0.620 |
Why?
| | Cell Movement | 9 | 2020 | 973 | 0.620 |
Why?
| | Mammary Glands, Animal | 4 | 2022 | 129 | 0.610 |
Why?
| | Humans | 94 | 2026 | 143560 | 0.600 |
Why?
| | Homeodomain Proteins | 5 | 2014 | 523 | 0.590 |
Why?
| | Alternative Splicing | 2 | 2018 | 243 | 0.590 |
Why?
| | Repressor Proteins | 6 | 2018 | 438 | 0.590 |
Why?
| | Mice | 25 | 2026 | 18378 | 0.580 |
Why?
| | Lung Neoplasms | 2 | 2026 | 2580 | 0.580 |
Why?
| | Cell Cycle | 4 | 2021 | 648 | 0.570 |
Why?
| | RNA Splicing Factors | 1 | 2018 | 58 | 0.560 |
Why?
| | Animals | 40 | 2026 | 38010 | 0.560 |
Why?
| | Up-Regulation | 7 | 2020 | 863 | 0.560 |
Why?
| | Tumor Microenvironment | 6 | 2026 | 732 | 0.560 |
Why?
| | Signal Transduction | 20 | 2026 | 5214 | 0.560 |
Why?
| | Mammary Neoplasms, Experimental | 3 | 2017 | 68 | 0.550 |
Why?
| | Carcinoma, Endometrioid | 2 | 2008 | 50 | 0.510 |
Why?
| | Xenograft Model Antitumor Assays | 8 | 2021 | 941 | 0.500 |
Why?
| | Gonadal Steroid Hormones | 1 | 2018 | 140 | 0.500 |
Why?
| | Lactation | 2 | 2022 | 192 | 0.500 |
Why?
| | Lipogenesis | 1 | 2016 | 65 | 0.490 |
Why?
| | MCF-7 Cells | 4 | 2025 | 130 | 0.480 |
Why?
| | Paclitaxel | 3 | 2017 | 236 | 0.480 |
Why?
| | Antibody Specificity | 1 | 2016 | 185 | 0.480 |
Why?
| | Receptor, trkB | 2 | 2012 | 35 | 0.460 |
Why?
| | Antineoplastic Agents | 6 | 2018 | 2195 | 0.460 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2015 | 57 | 0.450 |
Why?
| | Apoptosis | 11 | 2020 | 2519 | 0.440 |
Why?
| | Fatty Acid Synthase, Type I | 1 | 2014 | 11 | 0.440 |
Why?
| | Kynurenine | 4 | 2024 | 115 | 0.430 |
Why?
| | RNA Interference | 3 | 2015 | 474 | 0.420 |
Why?
| | Antibodies | 1 | 2016 | 402 | 0.420 |
Why?
| | Receptors, Steroid | 2 | 2010 | 46 | 0.410 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2017 | 441 | 0.410 |
Why?
| | Metformin | 2 | 2014 | 331 | 0.410 |
Why?
| | Carnitine O-Palmitoyltransferase | 2 | 2025 | 48 | 0.390 |
Why?
| | Gene Expression Regulation | 8 | 2016 | 2621 | 0.390 |
Why?
| | Chromatin | 1 | 2016 | 554 | 0.370 |
Why?
| | Mutation | 8 | 2025 | 4053 | 0.360 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 928 | 0.360 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2012 | 77 | 0.360 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2012 | 56 | 0.360 |
Why?
| | Neoadjuvant Therapy | 2 | 2020 | 438 | 0.350 |
Why?
| | Cystadenocarcinoma, Serous | 2 | 2024 | 84 | 0.350 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1827 | 0.350 |
Why?
| | Antineoplastic Agents, Hormonal | 5 | 2020 | 173 | 0.350 |
Why?
| | Disease Progression | 6 | 2018 | 2856 | 0.340 |
Why?
| | Endometrium | 2 | 2008 | 62 | 0.340 |
Why?
| | NF-kappa B | 3 | 2025 | 685 | 0.330 |
Why?
| | Transcriptional Activation | 5 | 2017 | 380 | 0.330 |
Why?
| | Mice, SCID | 4 | 2020 | 372 | 0.320 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2012 | 341 | 0.310 |
Why?
| | Tubulin Modulators | 1 | 2009 | 11 | 0.300 |
Why?
| | Cells | 1 | 2009 | 25 | 0.300 |
Why?
| | Estradiol | 6 | 2016 | 525 | 0.300 |
Why?
| | 3' Untranslated Regions | 4 | 2014 | 153 | 0.300 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 4 | 2011 | 24 | 0.300 |
Why?
| | Uterine Neoplasms | 2 | 2008 | 96 | 0.290 |
Why?
| | Cadherins | 4 | 2012 | 202 | 0.290 |
Why?
| | Killer Cells, Natural | 2 | 2025 | 475 | 0.290 |
Why?
| | Dirofilaria immitis | 3 | 2010 | 3 | 0.280 |
Why?
| | Neoplasms | 5 | 2022 | 2804 | 0.270 |
Why?
| | Mice, Nude | 5 | 2017 | 710 | 0.270 |
Why?
| | Feedback, Physiological | 2 | 2021 | 81 | 0.260 |
Why?
| | Trastuzumab | 2 | 2017 | 102 | 0.260 |
Why?
| | Cell Nucleus | 5 | 2017 | 612 | 0.250 |
Why?
| | Transfection | 5 | 2012 | 949 | 0.250 |
Why?
| | Microtubules | 1 | 2009 | 284 | 0.250 |
Why?
| | Epidermal Growth Factor | 4 | 2005 | 174 | 0.240 |
Why?
| | Phosphodiesterase 4 Inhibitors | 1 | 2026 | 11 | 0.240 |
Why?
| | Genetic Diseases, Inborn | 2 | 2017 | 46 | 0.240 |
Why?
| | Cyclopropanes | 1 | 2026 | 80 | 0.240 |
Why?
| | Aminopyridines | 1 | 2026 | 118 | 0.230 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2026 | 146 | 0.230 |
Why?
| | Fibrillin-1 | 1 | 2024 | 6 | 0.230 |
Why?
| | Mice, Inbred NOD | 3 | 2020 | 607 | 0.220 |
Why?
| | Anilides | 2 | 2016 | 84 | 0.220 |
Why?
| | Chemokine CCL2 | 1 | 2025 | 115 | 0.220 |
Why?
| | Marfan Syndrome | 1 | 2024 | 45 | 0.220 |
Why?
| | Down-Regulation | 6 | 2016 | 644 | 0.220 |
Why?
| | Cell Differentiation | 1 | 2012 | 2020 | 0.210 |
Why?
| | Gene Expression | 4 | 2020 | 1505 | 0.210 |
Why?
| | Microarray Analysis | 2 | 2016 | 118 | 0.210 |
Why?
| | Pharmacology, Clinical | 1 | 2023 | 9 | 0.200 |
Why?
| | Oligonucleotide Array Sequence Analysis | 5 | 2010 | 763 | 0.200 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 431 | 0.200 |
Why?
| | Tumor Cells, Cultured | 11 | 2020 | 974 | 0.180 |
Why?
| | Milk Proteins | 2 | 1999 | 35 | 0.180 |
Why?
| | Mammary Glands, Human | 2 | 2014 | 67 | 0.180 |
Why?
| | Genetic Variation | 2 | 2024 | 1008 | 0.180 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2022 | 98 | 0.180 |
Why?
| | Epithelium | 1 | 2022 | 314 | 0.180 |
Why?
| | Epigenesis, Genetic | 2 | 2018 | 686 | 0.170 |
Why?
| | Estrogens | 3 | 2020 | 372 | 0.170 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2022 | 80 | 0.170 |
Why?
| | Mice, Transgenic | 2 | 2017 | 2194 | 0.170 |
Why?
| | Lung | 2 | 2026 | 4101 | 0.170 |
Why?
| | Neoplasms, Second Primary | 1 | 2022 | 98 | 0.170 |
Why?
| | Promoter Regions, Genetic | 6 | 2014 | 1263 | 0.170 |
Why?
| | Neoplasm Proteins | 2 | 2018 | 443 | 0.160 |
Why?
| | Semaphorins | 1 | 2020 | 35 | 0.160 |
Why?
| | DNA-Binding Proteins | 6 | 2018 | 1524 | 0.160 |
Why?
| | Epoxy Compounds | 1 | 2020 | 32 | 0.160 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 65 | 0.160 |
Why?
| | Androgens | 1 | 2021 | 194 | 0.160 |
Why?
| | Gene Knockdown Techniques | 2 | 2020 | 336 | 0.160 |
Why?
| | Immune Tolerance | 1 | 2022 | 381 | 0.160 |
Why?
| | Respiratory Mucosa | 1 | 2022 | 325 | 0.160 |
Why?
| | STAT5 Transcription Factor | 3 | 2014 | 56 | 0.150 |
Why?
| | Neoplasm Metastasis | 3 | 2025 | 682 | 0.150 |
Why?
| | Transcription, Genetic | 9 | 2012 | 1511 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 388 | 0.150 |
Why?
| | RNA, Messenger | 7 | 2011 | 2852 | 0.150 |
Why?
| | Mitochondria | 1 | 2025 | 988 | 0.150 |
Why?
| | Pregnancy | 3 | 2022 | 7153 | 0.140 |
Why?
| | Prolactin | 1 | 1998 | 92 | 0.140 |
Why?
| | RNA, Small Interfering | 3 | 2020 | 637 | 0.140 |
Why?
| | Gene Amplification | 1 | 2018 | 108 | 0.140 |
Why?
| | Biomedical Research | 1 | 2025 | 699 | 0.140 |
Why?
| | Immunoblotting | 3 | 2010 | 313 | 0.140 |
Why?
| | Endometrial Hyperplasia | 2 | 2008 | 7 | 0.130 |
Why?
| | Binding Sites | 5 | 2016 | 1325 | 0.130 |
Why?
| | Antigens, CD | 1 | 2020 | 549 | 0.130 |
Why?
| | Mammary Tumor Virus, Mouse | 1 | 2017 | 45 | 0.130 |
Why?
| | Cluster Analysis | 4 | 2008 | 526 | 0.130 |
Why?
| | Dihydrotestosterone | 1 | 2017 | 44 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2018 | 267 | 0.130 |
Why?
| | Histone Acetyltransferases | 3 | 2006 | 63 | 0.130 |
Why?
| | Estrogen Receptor Modulators | 3 | 2008 | 17 | 0.130 |
Why?
| | Neoplasm Transplantation | 2 | 2014 | 253 | 0.130 |
Why?
| | Heterografts | 1 | 2017 | 138 | 0.130 |
Why?
| | Fatty Acids | 1 | 2020 | 452 | 0.130 |
Why?
| | Everolimus | 1 | 2017 | 111 | 0.130 |
Why?
| | Cyclohexanes | 1 | 2016 | 23 | 0.130 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 217 | 0.120 |
Why?
| | Tumor Suppressor Proteins | 2 | 2014 | 330 | 0.120 |
Why?
| | Enzyme Inhibitors | 3 | 2024 | 839 | 0.120 |
Why?
| | Trans-Activators | 4 | 2006 | 402 | 0.120 |
Why?
| | Carcinogenesis | 1 | 2018 | 232 | 0.120 |
Why?
| | Hyaluronan Receptors | 2 | 2014 | 104 | 0.120 |
Why?
| | Placenta | 1 | 2022 | 770 | 0.120 |
Why?
| | Ovary | 1 | 2017 | 227 | 0.120 |
Why?
| | Transplantation, Heterologous | 2 | 2014 | 197 | 0.110 |
Why?
| | Genes | 1 | 2015 | 229 | 0.110 |
Why?
| | Genetic Association Studies | 1 | 2017 | 377 | 0.110 |
Why?
| | Phosphoproteins | 2 | 2008 | 337 | 0.110 |
Why?
| | Hormones | 1 | 2015 | 138 | 0.110 |
Why?
| | Sequence Analysis, DNA | 2 | 2015 | 823 | 0.110 |
Why?
| | Exome | 1 | 2015 | 240 | 0.110 |
Why?
| | Tosyl Compounds | 1 | 2014 | 16 | 0.110 |
Why?
| | Drug Delivery Systems | 1 | 2017 | 372 | 0.100 |
Why?
| | Genes, Reporter | 2 | 2012 | 273 | 0.100 |
Why?
| | Ligands | 6 | 2023 | 670 | 0.100 |
Why?
| | Protein Transport | 1 | 2015 | 447 | 0.100 |
Why?
| | Sarcoma, Ewing | 1 | 2015 | 100 | 0.100 |
Why?
| | PTEN Phosphohydrolase | 1 | 2015 | 165 | 0.100 |
Why?
| | HEK293 Cells | 1 | 2016 | 748 | 0.100 |
Why?
| | In Situ Hybridization | 2 | 2010 | 321 | 0.100 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 1993 | 50 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2024 | 2417 | 0.100 |
Why?
| | Cells, Cultured | 2 | 2016 | 4182 | 0.100 |
Why?
| | Cellular Reprogramming | 1 | 2014 | 103 | 0.100 |
Why?
| | Neurotrophin 3 | 1 | 2012 | 10 | 0.100 |
Why?
| | Cell Adhesion | 2 | 2012 | 456 | 0.100 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 1043 | 0.100 |
Why?
| | Disease Models, Animal | 2 | 2021 | 4522 | 0.100 |
Why?
| | Autocrine Communication | 1 | 2012 | 40 | 0.100 |
Why?
| | Ketones | 1 | 1993 | 52 | 0.100 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2015 | 374 | 0.100 |
Why?
| | Metalloendopeptidases | 1 | 1992 | 59 | 0.090 |
Why?
| | Aromatase Inhibitors | 2 | 2014 | 58 | 0.090 |
Why?
| | Cysteine Endopeptidases | 1 | 1992 | 74 | 0.090 |
Why?
| | Family | 1 | 2017 | 683 | 0.090 |
Why?
| | Middle Aged | 7 | 2024 | 35342 | 0.090 |
Why?
| | Transduction, Genetic | 1 | 2012 | 135 | 0.090 |
Why?
| | Disease-Free Survival | 1 | 2014 | 720 | 0.090 |
Why?
| | Nuclear Proteins | 5 | 2000 | 749 | 0.090 |
Why?
| | Gene Silencing | 2 | 2014 | 201 | 0.090 |
Why?
| | Luciferases | 1 | 2012 | 152 | 0.090 |
Why?
| | Carrier Proteins | 2 | 2023 | 752 | 0.090 |
Why?
| | Zinc Finger E-box Binding Homeobox 2 | 1 | 2011 | 6 | 0.090 |
Why?
| | Receptors, Leptin | 1 | 2011 | 25 | 0.090 |
Why?
| | Tumor Burden | 1 | 2012 | 319 | 0.090 |
Why?
| | Tissue Array Analysis | 2 | 2008 | 51 | 0.090 |
Why?
| | Tubulin | 1 | 2012 | 146 | 0.090 |
Why?
| | Mice, Inbred C57BL | 2 | 2016 | 6043 | 0.080 |
Why?
| | GTPase-Activating Proteins | 1 | 2011 | 85 | 0.080 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2086 | 0.080 |
Why?
| | Fibronectins | 1 | 2011 | 136 | 0.080 |
Why?
| | Protein Biosynthesis | 2 | 2012 | 453 | 0.080 |
Why?
| | Microfilament Proteins | 1 | 2011 | 135 | 0.080 |
Why?
| | Cell Transdifferentiation | 1 | 2010 | 31 | 0.080 |
Why?
| | HeLa Cells | 5 | 2006 | 650 | 0.080 |
Why?
| | Retinoid X Receptors | 1 | 2010 | 38 | 0.080 |
Why?
| | Cyclins | 3 | 1999 | 101 | 0.080 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2010 | 346 | 0.080 |
Why?
| | DNA, Complementary | 4 | 2008 | 277 | 0.080 |
Why?
| | Breast | 2 | 2022 | 158 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 6 | 2010 | 994 | 0.080 |
Why?
| | Protein Isoforms | 4 | 2006 | 404 | 0.080 |
Why?
| | Prognosis | 3 | 2024 | 4152 | 0.070 |
Why?
| | Cell Line, Transformed | 1 | 2009 | 146 | 0.070 |
Why?
| | Inflammation | 1 | 2020 | 2881 | 0.070 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2023 | 209 | 0.070 |
Why?
| | Perilipin-1 | 1 | 2008 | 17 | 0.070 |
Why?
| | S100 Proteins | 1 | 2008 | 36 | 0.070 |
Why?
| | Glucose | 1 | 2013 | 1042 | 0.070 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3380 | 0.070 |
Why?
| | Leiomyoma | 1 | 2008 | 58 | 0.070 |
Why?
| | Drug Interactions | 1 | 2009 | 406 | 0.070 |
Why?
| | Aged | 5 | 2024 | 25322 | 0.070 |
Why?
| | Glycoproteins | 2 | 2024 | 356 | 0.070 |
Why?
| | Hysterectomy | 1 | 2008 | 139 | 0.070 |
Why?
| | Interleukin-6 | 2 | 2024 | 781 | 0.060 |
Why?
| | Receptor, IGF Type 1 | 1 | 2006 | 65 | 0.060 |
Why?
| | Molecular Sequence Data | 6 | 2010 | 2942 | 0.060 |
Why?
| | Stem Cells | 1 | 2010 | 619 | 0.060 |
Why?
| | Survival Rate | 2 | 2020 | 2003 | 0.060 |
Why?
| | Argentina | 1 | 2025 | 29 | 0.060 |
Why?
| | Precancerous Conditions | 1 | 2006 | 165 | 0.060 |
Why?
| | Canada | 2 | 2017 | 433 | 0.060 |
Why?
| | Thromboplastin | 1 | 2004 | 73 | 0.050 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 3 | 1999 | 127 | 0.050 |
Why?
| | Neoplasm Staging | 1 | 2008 | 1416 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2024 | 57 | 0.050 |
Why?
| | Obesity | 1 | 2017 | 3041 | 0.050 |
Why?
| | Hypoglycemic Agents | 1 | 2013 | 1394 | 0.050 |
Why?
| | Protein Binding | 4 | 2010 | 2261 | 0.050 |
Why?
| | Ovariectomy | 2 | 2017 | 160 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2024 | 312 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 471 | 0.050 |
Why?
| | Postmenopause | 3 | 2017 | 377 | 0.050 |
Why?
| | Congresses as Topic | 1 | 2025 | 226 | 0.050 |
Why?
| | Amino Acid Sequence | 4 | 2010 | 2165 | 0.050 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 1 | 2023 | 29 | 0.050 |
Why?
| | Genome, Human | 1 | 2024 | 429 | 0.050 |
Why?
| | ErbB Receptors | 1 | 2005 | 617 | 0.050 |
Why?
| | Immune Evasion | 1 | 2022 | 64 | 0.050 |
Why?
| | Larva | 2 | 1993 | 239 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2024 | 233 | 0.040 |
Why?
| | Biology | 1 | 2022 | 92 | 0.040 |
Why?
| | Promegestone | 4 | 2005 | 33 | 0.040 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 167 | 0.040 |
Why?
| | Mifepristone | 2 | 2000 | 63 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2004 | 550 | 0.040 |
Why?
| | Drug Resistance | 2 | 2000 | 153 | 0.040 |
Why?
| | Adult | 4 | 2016 | 40013 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2024 | 589 | 0.040 |
Why?
| | Fibroblasts | 1 | 2006 | 1044 | 0.040 |
Why?
| | Mammals | 1 | 2022 | 291 | 0.040 |
Why?
| | Zinc | 1 | 2024 | 300 | 0.040 |
Why?
| | GPI-Linked Proteins | 1 | 2020 | 78 | 0.040 |
Why?
| | Antigens, Nuclear | 1 | 2000 | 16 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2015 | 11365 | 0.040 |
Why?
| | Exons | 2 | 1999 | 359 | 0.040 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2000 | 99 | 0.040 |
Why?
| | Postpartum Period | 1 | 2022 | 352 | 0.040 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1999 | 55 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 831 | 0.040 |
Why?
| | Adenocarcinoma | 1 | 2006 | 911 | 0.040 |
Why?
| | Young Adult | 1 | 2016 | 13972 | 0.040 |
Why?
| | Receptor Cross-Talk | 1 | 1998 | 21 | 0.040 |
Why?
| | Immunological Synapses | 1 | 2018 | 17 | 0.040 |
Why?
| | p300-CBP Transcription Factors | 1 | 2018 | 27 | 0.040 |
Why?
| | STAT1 Transcription Factor | 1 | 1998 | 71 | 0.040 |
Why?
| | DNA Helicases | 1 | 2000 | 145 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2008 | 8072 | 0.040 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2018 | 143 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 1998 | 191 | 0.030 |
Why?
| | Oxygenases | 1 | 1997 | 13 | 0.030 |
Why?
| | Drug Synergism | 1 | 1998 | 370 | 0.030 |
Why?
| | Receptor, ErbB-3 | 1 | 2017 | 46 | 0.030 |
Why?
| | Biological Transport | 1 | 1998 | 412 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1252 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2020 | 375 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 1998 | 302 | 0.030 |
Why?
| | Male | 3 | 2021 | 71500 | 0.030 |
Why?
| | Consanguinity | 1 | 2017 | 50 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2005 | 1314 | 0.030 |
Why?
| | STAT3 Transcription Factor | 1 | 1998 | 211 | 0.030 |
Why?
| | Ribosomal Proteins | 1 | 1997 | 93 | 0.030 |
Why?
| | Carcinogens | 1 | 1997 | 126 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 273 | 0.030 |
Why?
| | Steroids | 1 | 2017 | 165 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 1999 | 450 | 0.030 |
Why?
| | Sequence Alignment | 2 | 2010 | 367 | 0.030 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2000 | 403 | 0.030 |
Why?
| | Siblings | 1 | 2017 | 217 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1091 | 0.030 |
Why?
| | Macrophages | 1 | 2024 | 1506 | 0.030 |
Why?
| | Pedigree | 1 | 2017 | 513 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 453 | 0.030 |
Why?
| | Nuclear Receptor Co-Repressor 1 | 3 | 2000 | 15 | 0.030 |
Why?
| | Histones | 2 | 2014 | 666 | 0.030 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2015 | 26 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2017 | 1272 | 0.030 |
Why?
| | Base Sequence | 3 | 2008 | 2199 | 0.030 |
Why?
| | Keratin-5 | 1 | 2014 | 48 | 0.030 |
Why?
| | Nuclear Receptor Coactivator 1 | 2 | 2006 | 10 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2017 | 740 | 0.030 |
Why?
| | Genetic Testing | 1 | 2017 | 474 | 0.030 |
Why?
| | Testosterone | 1 | 2017 | 423 | 0.030 |
Why?
| | DNA Primers | 2 | 2008 | 518 | 0.020 |
Why?
| | Dipeptides | 1 | 1993 | 56 | 0.020 |
Why?
| | Chromatography | 1 | 1992 | 22 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2017 | 654 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 1993 | 415 | 0.020 |
Why?
| | Elastin | 1 | 1992 | 79 | 0.020 |
Why?
| | Hydrolysis | 1 | 1992 | 198 | 0.020 |
Why?
| | Protease Inhibitors | 1 | 1992 | 104 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 549 | 0.020 |
Why?
| | Genotype | 1 | 2017 | 1877 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5308 | 0.020 |
Why?
| | Blotting, Northern | 1 | 2010 | 201 | 0.020 |
Why?
| | Oligopeptides | 1 | 1992 | 266 | 0.020 |
Why?
| | Cell Size | 1 | 2010 | 91 | 0.020 |
Why?
| | Cell Dedifferentiation | 1 | 2010 | 31 | 0.020 |
Why?
| | COS Cells | 2 | 2003 | 179 | 0.020 |
Why?
| | DNA, Helminth | 1 | 2010 | 26 | 0.020 |
Why?
| | Collagen | 1 | 1992 | 457 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2010 | 88 | 0.020 |
Why?
| | NIH 3T3 Cells | 1 | 2010 | 150 | 0.020 |
Why?
| | Nuclear Receptor Co-Repressor 2 | 2 | 2000 | 14 | 0.020 |
Why?
| | Matrix Metalloproteinase 11 | 1 | 2008 | 4 | 0.020 |
Why?
| | DNA Methylation | 1 | 2014 | 667 | 0.020 |
Why?
| | Rats | 1 | 2017 | 5610 | 0.020 |
Why?
| | Phosphorylation | 2 | 2005 | 1781 | 0.020 |
Why?
| | Phenotype | 1 | 2017 | 3211 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2008 | 83 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2005 | 2056 | 0.020 |
Why?
| | Cell Division | 2 | 2000 | 806 | 0.020 |
Why?
| | Myometrium | 1 | 2008 | 39 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 1992 | 558 | 0.020 |
Why?
| | Androstadienes | 1 | 2008 | 74 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2008 | 162 | 0.020 |
Why?
| | United States | 1 | 2025 | 15553 | 0.020 |
Why?
| | Trypan Blue | 1 | 2006 | 6 | 0.020 |
Why?
| | Comet Assay | 1 | 2006 | 16 | 0.020 |
Why?
| | Nuclear Receptor Coactivator 3 | 1 | 2006 | 5 | 0.020 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2006 | 57 | 0.020 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2006 | 74 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2006 | 83 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2006 | 153 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2006 | 104 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 2 | 2000 | 677 | 0.010 |
Why?
| | Biomarkers | 1 | 2017 | 4241 | 0.010 |
Why?
| | Amino Acid Motifs | 1 | 2006 | 226 | 0.010 |
Why?
| | Androstenes | 1 | 2005 | 17 | 0.010 |
Why?
| | Caspase 3 | 1 | 2006 | 251 | 0.010 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2006 | 160 | 0.010 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2005 | 37 | 0.010 |
Why?
| | Levonorgestrel | 1 | 2005 | 36 | 0.010 |
Why?
| | Neuroblastoma | 1 | 2006 | 165 | 0.010 |
Why?
| | Desogestrel | 1 | 2005 | 46 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 2006 | 368 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 2005 | 147 | 0.010 |
Why?
| | Sucrose | 1 | 2004 | 111 | 0.010 |
Why?
| | DNA Repair | 1 | 2006 | 250 | 0.010 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2006 | 318 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 2006 | 488 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2006 | 863 | 0.010 |
Why?
| | Microscopy, Confocal | 1 | 2004 | 326 | 0.010 |
Why?
| | Reactive Oxygen Species | 1 | 2006 | 642 | 0.010 |
Why?
| | DNA Damage | 1 | 2006 | 446 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2003 | 397 | 0.010 |
Why?
| | Progesterone Congeners | 1 | 2002 | 15 | 0.010 |
Why?
| | Mutagenesis | 1 | 2003 | 184 | 0.010 |
Why?
| | Uterus | 1 | 2003 | 221 | 0.010 |
Why?
| | Dimerization | 1 | 2002 | 197 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 11737 | 0.010 |
Why?
| | Cell Survival | 1 | 2004 | 1136 | 0.010 |
Why?
| | Plasmids | 1 | 2002 | 371 | 0.010 |
Why?
| | Ku Autoantigen | 1 | 2000 | 11 | 0.010 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2000 | 16 | 0.010 |
Why?
| | Glutathione Transferase | 1 | 2000 | 99 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2003 | 1369 | 0.010 |
Why?
| | Culture Techniques | 1 | 1999 | 74 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2006 | 1474 | 0.010 |
Why?
| | Methionine | 1 | 2000 | 158 | 0.010 |
Why?
| | Peptide Fragments | 1 | 2003 | 698 | 0.010 |
Why?
| | Growth Substances | 1 | 1999 | 140 | 0.010 |
Why?
| | Estrogen Receptor beta | 1 | 1999 | 43 | 0.010 |
Why?
| | Cricetinae | 1 | 1999 | 300 | 0.010 |
Why?
| | Phosphotyrosine | 1 | 1998 | 40 | 0.010 |
Why?
| | Receptors, Growth Factor | 1 | 1998 | 56 | 0.010 |
Why?
| | RNA | 1 | 2005 | 933 | 0.010 |
Why?
| | Premenopause | 1 | 1999 | 120 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2017 | 16741 | 0.010 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 1998 | 155 | 0.010 |
Why?
| | Sp1 Transcription Factor | 1 | 1998 | 25 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1999 | 517 | 0.010 |
Why?
| | Estrogen Antagonists | 1 | 1998 | 46 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 1998 | 151 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 1998 | 183 | 0.010 |
Why?
| | Isomerism | 1 | 1997 | 54 | 0.010 |
Why?
| | Leucine Zippers | 1 | 1997 | 16 | 0.010 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 1998 | 273 | 0.010 |
Why?
| | Gene Deletion | 1 | 1999 | 394 | 0.010 |
Why?
| | Yeasts | 1 | 1997 | 52 | 0.010 |
Why?
| | Autoantigens | 1 | 2000 | 427 | 0.010 |
Why?
| | Blotting, Western | 1 | 1998 | 1223 | 0.010 |
Why?
| | Child | 1 | 2015 | 22725 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1998 | 1062 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 7031 | 0.010 |
Why?
| | Cell Line | 1 | 1998 | 2897 | 0.010 |
Why?
| | Cytokines | 1 | 1999 | 2097 | 0.010 |
Why?
| | Models, Biological | 1 | 1998 | 1831 | 0.010 |
Why?
|
|
Richer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|